Interleukin-6 May Boost Prediction of Obesity-Related Cancers
By Lori Solomon HealthDay Reporter
TUESDAY, Sept. 3, 2024 -- In patients with newly diagnosed type 2 diabetes, baseline interleukin-6 (IL-6) levels may enhance prediction of new-onset obesity-related cancers, according to a study scheduled to be presented at the annual meeting of the European Association for the Study of Diabetes, being held from Sept. 9 to 13 in Madrid.
Mathilde Dahlin Bennetsen, from the Steno Diabetes Center Odense at Odense University Hospital in Denmark, and colleagues explored whether IL-6, tumor necrosis factor-alpha (TNF-α), and high-sensitivity C-reactive protein (hsCRP) can serve as predictive biomarkers for obesity-related cancers in patients recently diagnosed with type 2 diabetes. The analysis included 6,466 individuals followed for a median 8.8 years.
The researchers found that baseline IL-6 levels were associated with a higher subsequent obesity-related cancer risk. A one standard deviation increase in log-transformed IL-6 was tied to a 19 percent increased risk for obesity-related cancers in an adjusted analysis (hazard ratio, 1.19; 95 percent confidence interval, 1.07 to 1.31). There was no strong association seen between TNF-α (hazard ratio, 1.08; 95 percent confidence interval, 0.98 to 1.19) or hsCRP (hazard ratio, 1.08; 95 percent confidence interval, 0.97 to 1.21) and obesity-related cancers. In 4,335 participants with available smoking habit information, similar associations were seen. The addition of IL-6 to a cancer prediction model conferred a small but statistically significant increase in the C-index, from 0.685 to 0.693, whereas the addition of hsCRP or TNF-α did not result in improvements in model performance.
"Understanding which individuals are at higher risk for these cancers would allow for more targeted and effective monitoring and early detection, potentially improving outcomes through earlier intervention and personalized treatment," Bennetsen said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
Incidence Rates of Appendiceal Adenocarcinoma Increasing
MONDAY, June 16, 2025 -- The incidence rates of appendiceal adenocarcinoma (AA) increased after 1945, according to a study published online June 10 in the Annals of Internal...
CT Colonography Cost-Effective, Clinically Effective for CRC Screening
MONDAY, June 16, 2025 -- Computed tomography colonography (CTC) is cost-effective and clinically effective for colorectal cancer (CRC) screening, according to a study published...
Doctors' Preferences for Their Own End-of-Life Care? No Life-Sustaining Practices
FRIDAY, June 13, 2025 -- Many physicians would personally prefer to avoid life-sustaining practices if they had advanced cancer or Alzheimer disease, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.